Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Background. Intraperitoneal radioactive phosphorus (phosphorus‐32) has been used in ovarian cancer during the last three decades. In the current study, the survival results, the patterns of recurrence, morbidity rates, and phosphorus‐32 distribution scintigrams were reviewed in 313 patients treated with phosphorus‐32 colloid. Methods. Between July 1982 and July 1988, 245 patients with epithelial ovarian carcinoma were treated with phosphorus‐32 as primary adjuvant treatment; 59 patients received phosphorus‐32 as consolidating therapy after negative results during second‐look surgery and 9, after positive findings during second‐look laparotomy. Fifty patients with negative second‐look findings were assigned randomly to receive phosphorus‐32 or no treatment. The phosphorus‐32 distribution was studied by scintigraphic imaging in 297 patients. Results. The actuarial 5‐year crude survival rate was 81% in the group treated with phosphorus‐32 adjuvantly and 79% in the group treated after second‐look surgery. Crude and disease‐free survival rates were similar in both groups randomized at second‐look surgery to receive either phosphorus‐32 or no treatment. Phosphorus‐32 scintigraphy showed major isotopic accumulations in 48 (16%) patients. There were two deaths (0.6%), which, at least partly, could be attributed to the phosphorus‐32 treatment. Small bowel obstruction without tumor recurrence occurred in 22 (7%) patients (13 treated surgically and 9 medically) and was not related to any patient characteristic, including phosphorus‐32 distribution. Conclusions. Phosphorus‐32 therapy was associated with a considerable number of bowel complications. The occurrence of small bowel obstruction could not be predicted by any patient characteristic. Without an untreated observation group, the authors were unsure whether adjuvant phosphorus‐32 treatment conferred a survival advantage.
Background. Intraperitoneal radioactive phosphorus (phosphorus‐32) has been used in ovarian cancer during the last three decades. In the current study, the survival results, the patterns of recurrence, morbidity rates, and phosphorus‐32 distribution scintigrams were reviewed in 313 patients treated with phosphorus‐32 colloid. Methods. Between July 1982 and July 1988, 245 patients with epithelial ovarian carcinoma were treated with phosphorus‐32 as primary adjuvant treatment; 59 patients received phosphorus‐32 as consolidating therapy after negative results during second‐look surgery and 9, after positive findings during second‐look laparotomy. Fifty patients with negative second‐look findings were assigned randomly to receive phosphorus‐32 or no treatment. The phosphorus‐32 distribution was studied by scintigraphic imaging in 297 patients. Results. The actuarial 5‐year crude survival rate was 81% in the group treated with phosphorus‐32 adjuvantly and 79% in the group treated after second‐look surgery. Crude and disease‐free survival rates were similar in both groups randomized at second‐look surgery to receive either phosphorus‐32 or no treatment. Phosphorus‐32 scintigraphy showed major isotopic accumulations in 48 (16%) patients. There were two deaths (0.6%), which, at least partly, could be attributed to the phosphorus‐32 treatment. Small bowel obstruction without tumor recurrence occurred in 22 (7%) patients (13 treated surgically and 9 medically) and was not related to any patient characteristic, including phosphorus‐32 distribution. Conclusions. Phosphorus‐32 therapy was associated with a considerable number of bowel complications. The occurrence of small bowel obstruction could not be predicted by any patient characteristic. Without an untreated observation group, the authors were unsure whether adjuvant phosphorus‐32 treatment conferred a survival advantage.
The problem of treating recurrent, cystic craniopharyngioma is at times an extremely trying one. When each craniotomy results in improvement of visual fields, but then when timre is rapidly recurring general symptomatology and once more loss of sight occurs, both the patient and the surgeon begin to wonder if the short span of improvement is worth the hardships incident to another craniotomy. Drawing on the experience gained by others in treating neoplastic effusions of various body cavities with radioactive chromic phosphate, we decided to use this material to treat a case of recurrent cystic craniopharyngioma which had become a complete enigma to us in regard to further therapy. This has, we feel, resulted in a solution of the problem as illustrated in the following case report.Case Report 1st Admission. TCT, No. 50479M, an 18-year-old Latin-American barber from Odem, Texas, was first seen at the University of Texas Medical Branch Hospital on Jan. 6, 1958. He had never noted any visual deficit until 1 month previously when he began to complain of failing eyesight which became increasingly worse to the point where he felt he was blind in his left eye. He could still see out of his right eye, but he required help in walking in order to avoid running into objects. For ~ or 8 weeks he had had dull headaches which at times were associated with nausea and vomiting and which were relieved by aspirin. These had become much more severe in the 8 days prior to admission.The only significant finding in his past history was that he had been treated in a tuberculosis sanatorimn for 4 years and during that period had had a thoracotomy.When examined, he was somewhat apathetic and sluggish in his responses. With the left eye he could perceive only light and movement of hands, but in the right eye, ~0/100 vision was preserved. Visual fields revealed a temporal-field deficit on the right; the left could not be tested.Roentgenograms of the skull showed enlargement and erosion of the sella with decalcification of the clinoid processes. There was no pathologic calcification. Pneumoencephalography indicated a filling defect of the anterior part of the 3rd ventricle and the chiasmatic cistern, while arteriography confirmed the fact that a suprasellar mass was present.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.